Fostamatinib

Generic Name: Fostamatinib

Brand Names: Tavalisse, Tavlesse

Drug Type: Small Molecule

Chemical Formula: C_₂₃H_₂₆FN_₆O_₉P

CAS Number: 901119-35-5

Unique Ingredient Identifier: SQ8A3S5101

Background: Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP . Fostamatinib has also been granted orphan drug status by the FDA .

Recently, fostamatinib has been identified as a potential therapeutic for controlling acute respiratory distress syndrome (ARDS) in patients with severe COVID-19 through its ability to modulate the SYK kinase.

Indication: 用于治疗对既往治疗反应不足的慢性免疫性血小板减少症（ITP）成年患者的血小板减少症。

Associated Conditions: Chronic immune thrombocytopenia

Clinical Trials

Study in Healthy Males to Assess the Bioavailability of 4 Different Fostamatinib Tablets

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Fostamatinib

First Posted Date: 2011-07-04

Last Posted Date: 2011-10-28

Lead Sponsor: AstraZeneca

Target Recruit Count: 24

Registration Number: NCT01387308

Locations: 🇺🇸
Research Site, Overland Park, Kansas, United States

Effects of Administration of Fostamatinib on Blood Concentrations of Digoxin in Healthy Subjects

Phase 1

Completed

Conditions: Healthy Volunteers
Rheumatoid Arthritis

Interventions: Drug: Digoxin
Drug: Fostamatinib

First Posted Date: 2011-05-18

Last Posted Date: 2011-10-06

Lead Sponsor: AstraZeneca

Target Recruit Count: 21

Registration Number: NCT01355354

Locations: 🇬🇧
Research Site, London, United Kingdom

Effects of Administration of Fostamatinib on Blood Concentrations of Rifampicin in Healthy Subjects.

Phase 1

Completed

Conditions: Healthy Volunteers
Rheumatoid Arthritis

Interventions: Drug: fostamatinib
Drug: rifampicin

First Posted Date: 2011-04-15

Last Posted Date: 2011-07-22

Lead Sponsor: AstraZeneca

Target Recruit Count: 15

Registration Number: NCT01336218

Locations: 🇺🇸
Research Site, Overland Park, Kansas, United States

Effects of Administration of Fostamatinib on Blood Concentrations of Warfarin in Healthy Subjects

Phase 1

Completed

Conditions: Rheumatoid Arthritis
Healthy Subjects

Interventions: Drug: warfarin
Drug: fostamatinib

First Posted Date: 2011-03-09

Last Posted Date: 2013-01-31

Lead Sponsor: AstraZeneca

Target Recruit Count: 15

Registration Number: NCT01311622

Locations: 🇬🇧
Research Site, London, United Kingdom

Effects of Administration of Fostamatinib on Blood Concentrations of Pioglitazone in Healthy Subjects

Phase 1

Completed

Conditions: Rheumatoid Arthritis
Healthy Volunteers
Pharmacokinetics
Pioglitazone
Drug-drug Interaction
Amount of Pioglitazone in Blood

Interventions: Drug: fostamatinib
Drug: pioglitazone

First Posted Date: 2011-03-07

Last Posted Date: 2011-07-07

Lead Sponsor: AstraZeneca

Target Recruit Count: 15

Registration Number: NCT01309854

Locations: 🇺🇸
Research Site, Overland Park, Kansas, United States

Effects of Administration of Fostamatinib on Blood Concentrations of an Oral Contraceptive in Healthy Female Subjects

Phase 1

Completed

Conditions: Scientific Terminology Rheumatoid Arthritis, Healthy Female Volunteers, Pharmacokinetics, Oral Contraceptive, Drug-drug Interaction
Laymen Terminology Level of Oral Contraceptive in Blood, Oral Contraceptive, Rheumatoid Arthritis, Drug -Drug Interaction